The record

LegislationLegislation· Jun 2025
HR 1082 Passed House — in Senate

Sponsored by John R. Moolenaar (R)

Shandra Eisenga Human Cell and Tissue Product Safety Act

Establishes civil penalties for violations of human cell and tissue product regulations and requires FDA education and transparency efforts.

Tradeoff

Creates enforcement penalties up to $10 million per proceeding for violations of tissue product rules. Requires FDA to spend resources on workshops, public reporting, and educational materials about tissue regulation.

What's in it

See official bill text

Increases spending by $2 million over 2026-2030 and collects less than $500,000 in civil penalties over 2026-2035.

The $2 million federal cost is just administrative overhead for to conduct an awareness campaign, develop educational materials, and direct FDA activities—the actual regulatory burden falls on human cell and tissue product manufacturers and handlers who must comply with expanded oversight requirements.

H.R. 1082, Shandra Eisenga Human Cell and Tissue Product Safety Act · Nov 2025

Passed the House by on June 23, 2025 — sitting in the Senate.

  1. House

    Introduced

    (Feb 6, 2025)

  2. House

    Committee on Energy and Commerce(Feb 6, 2025)

  3. House

    The Committee on Energy and Commerce voted to send it to the floor

    Reported by (Apr 29, 2025)

    Committee report H. Rept. 119-160.

  4. House

    Passage of the bill

    Passed by (Jun 23, 2025)

    No individual votes were recorded.

  5. Senate

    Received from the House

    on Health, Education, Labor, and Pensions(Jun 24, 2025)